Cloudbreak Pharma Inc. (HKG:2592)

Market Cap	1.89B
Revenue (ttm)	80.40M +2,074.5%
Net Income	-328.39M
EPS	-1.32
Shares Out	838.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	837,000
Average Volume	1,017,150
Open	2.260
Previous Close	2.280
Day's Range	2.110 - 2.260
52-Week Range	2.160 - 9.740
Beta	n/a
RSI	29.32
Earnings Date	Jun 23, 2026

About Cloudbreak Pharma

Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingre...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 60
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2592

Financial Performance

In 2024, Cloudbreak Pharma's revenue was $10.21 million, an increase of 1060.68% compared to the previous year's $880,000. Losses were -$99.13 million, -23.40% less than in 2023.

Financial numbers in USD